Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infectionโ as manifested by febrile neutropeniaโ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02626338
- Locations
- ๐บ๐ธ
City of Hope Medical Center, Duarte, California, United States
๐บ๐ธHouston Methodist, Houston, Texas, United States
๐บ๐ธUniversity of Arkansas, Little Rock, Arkansas, United States
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 500
- Registration Number
- NCT02582697
- Locations
- ๐ฆ๐บ
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
๐ฆ๐บPrince of Wales Hospital, Sydney, New South Wales, Australia
๐ฆ๐บRoyal Adelaide Hospital, Adelaide, South Australia, Australia
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
- Conditions
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 43
- Registration Number
- NCT02494921
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
๐บ๐ธUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2019-01-18
- Target Recruit Count
- 3
- Registration Number
- NCT02478125
- Locations
- ๐บ๐ธ
Johns Hopkins University, Baltimore, Maryland, United States
Ruxolitinib in Combination With Autotransplant
- Conditions
- Interventions
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Marina Kremyanskaya
- Registration Number
- NCT02469974
Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study
- Conditions
- Interventions
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2017-08-29
- Target Recruit Count
- 65
- Registration Number
- NCT02451033
- Locations
- ๐ฎ๐ณ
Dept. of Hepatology, PGIMER, Chandigarh, Chandigarh, India
๐ฎ๐ณDepartment of Hepatology,Postgraduate Institute of Medical Education and Research, Chandigarh, India
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02447055
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 320
- Registration Number
- NCT02436707
- Locations
- ๐จ๐ฆ
BCCA - Vancouver, Vancouver, British Columbia, Canada
๐จ๐ฆAllan Blair Cancer Centre, Regina, Saskatchewan, Canada
๐จ๐ฆCross Cancer Institute, Edmonton, Alberta, Canada
Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Seoul St. Mary's Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT02427919
- Locations
- ๐ฐ๐ท
Seoul St. Mary's Hospital, Seoul, Banpodaero 222, Korea, Republic of
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
- Conditions
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT02423915
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.